Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
By C. Massard, M. Gordon, Sunil Sharma, S. Rafii, Z. Wainberg, J. Luke, T. Curiel, G. Colón-Otero, O. Hamid, R. Sanborn and 9 more. Journal of Clinical Oncology, 2016
723 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/4b17862a4df8429f21286cda43166ea6d69ffc6c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “In 17 February 2016, the FDA granted Breakthrough Therapy designation for durvalumab (Imfinzi) human monoclonal antibody directed against PD-L1, for the treatment of patients with PD-L1-positive inoperable or metastatic urothelial bladder cancer whose tumor has progressed during or after one standar”
- Immune Checkpoint Inhibitors in Cancer Therapy (2022, methodology): “It was designated by the FDA as a breakthrough therapy in February 2016 based on early clinical data from a Phase I trial for treating patients with metastatic urothelial bladder cancer whose tumour cells express PD-L1 and who had advanced disease during or after one standard platinum-containing che”
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, positive): “Durvalumab received FDA approval on May 1, 2017 for the treatment of platinum-refractory locally advanced or metastatic UC based on results from Study 1108 [37].”
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (2017, background): “Data were missing as follows: ECOG performance-status score (10 patients), smoking status (4), histologic type (2), tumor PD-L1 combined positive score 1% cutoff (14), tumor PD-L1 combined positive score 10% cutoff (16), location of primary tumor (1), location of metastases (2), liver metastases (1)”